Is there any clinical reason to administer anticoagulant therapy to patients with the Jugular Vein Nutcracker syndrome?

Letter to the Editor regarding the paper "Neurosurgical implications of the Jugular Vein Nutcracker (JVN)" by Angelini C. et al., published on Veins and Lymphatics 2023;12:11892 (doi:10.4081/vl.2023.11892)

Enrico Nastro Siniscalchi,¹ Giovanni Raffa²

¹Division of Maxillofacial Surgery, BIOMORF Department, University of Messina; ²Division of Neurosurgery, BIOMORF Department, University of Messina, Italy

Dear Editor,

We have read with great interest the article titled "Neurosurgical implications of the Jugular Vein Nutcracker (JVN)" by Angelini C. *et al.*, published on "Veins and Lymphatics".¹

The article focuses attention on the Jugular Vein Nutcracker (JVN) syndrome, which is usually underestimated and can be associated with several pathophysiological patterns that have previously been described in the most recent literature. We, therefore,

Correspondence: Giovanni Raffa, Division of Neurosurgery, BIO-MORF Department, University of Messina, via Consolare Valeria 1, 98125, Messina, Italy.

Tel. +39.0902212865. E-mail: giovanni.raffa@unime.it

Key words: Eagle Syndrome, Jugular Nuteracker Syndrome, styloid process, venous thrombosis.

Authors' contributions: all the authors made a substantive intellectual contribution. All the authors have read and approved the final version of the manuscript and agreed to be held accountable for all aspects of the work.

Conflict of interest: the authors declare no potential conflict of interest.

Funding: none.

Availability of data and materials: all data generated or analyzed during this study are included in this published article.

Received: 14 November 2023. Accepted: 17 November 2023. Early view: 23 November 2023.

©Copyright: the Author(s), 2023 Licensee PAGEPress, Italy Veins and Lymphatics 2023; 12:12088 doi:10.4081/vl.2023.12088

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher. would like to congratulate the authors for their interesting review of published studies on this condition, which sheds light on the JVN syndrome.

As a matter of fact, in recent years, we assisted to growing scientific interest in the JVN and its different clinical manifestations, some of them also being life-threatening.² In particular, venous thrombosis above the level of venous compression seems to be a common complication in these patients. However, rarely JVN is promptly recognized as the primary cause of thrombosis. In many cases, the JVN still remains not diagnosed, or it is disclosed months or years after the thrombotic event. That may lead to recurrent thrombotic phenomena, which are classified as "of unknown origin". In our opinion, such a recent increasing interest in the JVN syndrome may help clinicians to better clarify the real incidence of this condition, which could be related to different clinical patterns, including cerebral sinuses thrombosis,³ nonaneurysmal subarachnoid hemorrhage,⁴ thrombosis of the subclavian vein,⁵ and even pulmonary embolism.²

In our opinion, some issues still deserve attention and some discussion, especially regarding potential life-threatening venous thrombosis events:

- 1. Before surgical treatment of JVN or in case of impossibility of performing the operation (*e.g.* patient's refusal to undergo surgery), should the clinicians consider the option of anticoagulant therapy in order to prevent Upper Extremity Deep Vein Thrombosis (UEDVT) or catastrophic events like cerebral sinuses thrombosis or pulmonary embolism?
- Could in such cases be useful to stratify the risk of UEDVT through the use of specific mi-RNAs as markers of prethrombotic status as recently proposed by Ten Cate V. *et al.*?⁶

We sincerely hope these open questions could stimulate the discussion about the best clinical management of the JVN syndrome patients and reduce the occurrence of JVN-connected lifethreatening events, even in cases in which such a condition is highly suspectable but not diagnosed, yet.

References

- Angelini C, Mantovani G, Cavallo MA, et al. Neurosurgical implications of the Jugular Vein Nutcracker. Veins and Lymphatics. 2023;12:11892.
- Siniscalchi EN, Raffa G, Germano A, De Ponte FS. Is Eagle jugular syndrome an underestimated potentially life-threatening disease? The Canadian journal of neurological sciences Le Journal Canadien des Sciences Neurologiques. 2020:1-5.
- Dashti SR, Nakaji P, Hu YC, et al. Styloidogenic jugular venous compression syndrome: diagnosis and treatment: case report. Neurosurgery. 2012;70:E795-9.



- Scerrati A, De Bonis P, Zamboni P, et al. A New Insight in Nonaneurysmal Subarachnoid Hemorrhage: The Potential Role of the Internal Jugular Veins. J Neurol Surg A Cent Eur Neurosurg. 2022;83:344-50.
- 5. Martinelli I. Unusual forms of venous thrombosis and throm-

bophilia. Pathophysiology of haemostasis and thrombosis. 2002;32:343-5.

6. Ten Cate V, Rapp S, Schulz A, et al. Circulating microRNAs predict recurrence and death following venous thromboembolism. J Thromb Haemost. 2023;21:2797-810.

Non-commercial use only